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Abstract
Mutations in the dysferlin gene cause the most frequent adult-onset limb girdle muscular dystrophy, LGMD2B. There is no
therapy. Dysferlin is a membrane protein comprised of seven, beta-sheet enriched, C2 domains and is involved in
Ca2+dependent sarcolemmal repair after minute wounding. On the protein level, point mutations in DYSF lead to
misfolding, aggregation within the endoplasmic reticulum, and amyloidogenesis. We aimed to restore functionality by
relocating mutant dysferlin. Therefore, we designed short peptides derived from dysferlin itself and labeled them to the cell
penetrating peptide TAT. By tracking fluorescently labeled short peptides we show that these dysferlin-peptides localize in
the endoplasmic reticulum. There, they are capable of reducing unfolded protein response stress. We demonstrate that the
mutant dysferlin regains function in membrane repair in primary human myotubes derived from patients’ myoblasts by the
laser wounding assay and a novel technique to investigate membrane repair: the interventional atomic force microscopy.
Mutant dysferlin abuts to the sarcolemma after peptide treatment. The peptide-mediated approach has not been taken
before in the field of muscular dystrophies. Our results could redirect treatment efforts for this condition.
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Introduction
Dysferlin is a type II membrane protein in the ferlin family with
a short extracellular 12 amino-acid domain. Dysferlin contains
seven C2 domains and is involved in Ca2+dependent membrane
repair after sarcolemmal microinjuries [1,2]. Limb-girdle muscular
dystrophy 2B (LGMD2B) is the most prominent dysferlinopathy
caused by mutations in the dysferlin (DYSF) gene [3,4]. Young
adults are affected and become wheel-chair bound within 15 years.
Other dysferlinopathies are Miyoshi myopathy, anterior-tibial
myopathy, idiopathic hyperCKemia, and rare congenital forms.
There is no treatment. DYSF is a large gene with 55 exons
encoding a 2080 amino-acid protein. More than 1000 DYSF
mutations have been described [5,6]. They are distributed evenly
over the entire length of the gene without mutational hotspots.
At least a third of the DYSF mutations are missense mutations.
We and others have demonstrated that DYSF missense mutations
cause dysferlin aggregation and misfolding, amyloid formation,
and subsequent degradation by the endoplasmic reticulum-
associated protein degradation machinery (ERAD) [7,8,9]. Protein
misfolding is the cause of numerous progressive hereditary and
acquired diseases including Alzheimer’s dementia, Parkinson’s
disease, and cystic fibrosis. Research directed towards protein
refolding and prevention of premature degradation in the
endoplasmic reticulum (ER) is intensively studied [10,11].
Dysferlinopathy is the first muscular dystrophy where faulty
protein aggregation was established. We asked whether mutant
dysferlin trapped within the ER could be redirected to the
sarcolemma and whether mutant dysferlin would be functional at
this site. We selected specifically designed dysferlin-peptides
coupled to the cell-penetrating peptide TAT (trans-activator of
transcription from human immunodeficiency virus type 1) and
demonstrate that these peptides support mutant dysferlin to
relocate and to regain proper function.
Results
Dysferlin-peptides Cause DYSF Missense Mutants to
Relocate to the Sarcolemma in C2C12 Cells
We selected two defined DYSF missense mutations for our
experimental design: DYSF p.G299R and DYSF p.L1341P. The
consequences of these mutations at the protein level have been
shown previously [6]. Both mutations lead to the absence of
dysferlin at the sarcolemma and to protein aggregation within the
ER. These variants were cloned into the pcDNA4/TO vector
containing the full-length human DYSF cDNA-GFP-tagged.
C2C12 murine muscle cells were transfected with wildtype (WT)
or mutant dysferlin. Transfection with WT dysferlin resulted in
membrane staining (Fig. 1A–C); however, the mutants as
expected, aggregated within the cells (Fig. 1D, G). We next
explored the effect of peptides specifically designed to resemble the
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e49603
respective DYSF mutations. We coupled 10mer and 15mer
dysferlin-peptides to the human immunodeficiency virus transac-
tivator protein at their N-terminal ends (Table 1 and Fig. S1).
Eleven hours after last addition of TAT-labeled dysferlin-peptides
to C2C12 cells, we detected dysferlin at sarcolemmal sites. This
effect was most efficient when the shortest peptides were used that
contained the mutated amino acid (Fig. 1E, H). Longer peptides
(15mer) caused a weaker membranous redistribution (Fig. 1I and
Fig. S2B); peptides reflecting the wildtype sequence led to a
dispersion of otherwise accumulated dysferlin but we were not able
to detect dysferlin at the muscle membrane (Fig. 1F and Fig. S2D).
All experiments were also performed in C2C12 cells harboring a
permanent knockdown of the dysferlin gene (not shown).
Dysferlin-peptides Cause Reallocation of DYSF Missense
Mutants in Primary Human myotubes
We next tested whether or not TAT-labeled dysferlin-peptides
would elicit an effect on primary human myotubes obtained from
patients with DYSF p.G299R and DYSF p.L1341P. Missense
mutated dysferlin accumulates within the myotubes (Fig. 2A and
D, Fig. S3) and does not localize to the sarcolemma as it can be
seen in multinucleated human muscle cells from normal controls
(Fig. 2F). Similar to the results seen in C2C12 cells, addition of
TAT-labeled specific peptides to dysferlin-deficient human myo-
tubes resulted in translocation of mutant dysferlin to the
sarcolemma (Fig. 2B and E, Fig. S3). Again, 10-mer peptides
containing the corresponding mutation were most effective.
Peptides corresponding to the wildtype sequence or nonsense
peptides (Fig. 2C, Fig. S3) did not show these effects on dysferlin
localization. Thus, the short peptides derived from mutant
dysferlin and coupled to TAT are effective in retargeting dysferlin
to the sarcolemma.
Missense Mutant dysferlin is Functional after Reallocation
We next tested the function of mutant dysferlin reallocated with
TAT-labeled dysferlin-peptides by two independent methods.
First, we performed laser wounding of the sarcolemma in primary
human myotubes. Due to the impaired membrane repair ability
dysferlin-deficient myofibers show influx of fluorescent dye into the
myotube [2]. We adapted the method to primary human
myotubes. Because of the smaller size of the myotubes as
compared to murine intact muscle fibers the wounding area was
only 2.562.5 mm. Compared to normal human myotubes (Fig. 3D
and E, video S4) dye influx was significantly increased in dysferlin-
mutants (Fig. 3A and E, video S1). TAT-labeled dysferlin-peptides
harboring the mutation significantly improve the ability of the
Figure 1. Dysferlin-peptides redirect mutant dysferlin in transfected C2C12 cells. C2C12 cells were transfected with either GFP-tagged
wildtype human dysferlin cDNA or missense-mutated dysferlin cDNA DYSF p.G299R or p.L1341P. Transfected cells were treated with TAT-labeled
dysferlin-peptides corresponding to the mutation. (A–C) Wildtype human dysferlin-GFP tagged. (A) Dysferlin-GFP. (B) Localization of dysferlin is
confirmed by immunostaining using an anti-dysferlin ab. (C) merge. (D–F) DYSF p.G299R-GFP tagged. Experiment performed 146. (D) No peptides
added. GFP-dysferlin is not expressed at the plasma membrane. (E) Peptide A2 (10-mer) added corresponding to DYSF p.G299R. GFP-dysferlin
relocalizes to sarcolemmal sites. (F) Peptide A1 corresponding to WT dysferlin added. Distribution of dysferlin is granular but not expressed at the
sarcolemma. (G–I) DYSF p.L1341P-GFP tagged. Experiment performed 126. (G) No peptides added. (H) Peptide B2 (10-mer) corresponding to DYSF
p.L1341P supports reallocation of dysferlin to the sarcolemma. (I) Peptide B4 (15-mer) corresponding to DYSF p.L1341P. 10mer peptides carrying the
corresponding mutation were most effective. Bar: 10 mm. Inserts represent enlarged boxed areas.
doi:10.1371/journal.pone.0049603.g001
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sarcolemma to reseal (Fig. 3C and E; video S3). Non-specific
peptides also elicited some effect on membrane resealing; however,
this effect did not reach statistical significance (Fig. 3B and E,
video S2).
We applied a second method to wound myotubes at the single-
cell level. We used atomic force microscopy to induce and visualize
membrane wounding and repair in normal and dysferlin-mutant
human myotubes. DYSF p.L1341P myotubes, untreated and
treated with TAT-labeled dysferlin-peptides, were wounded by
applying a 2 mm longitudinal cut with a force of 40 nN with a
CSC37 cantilever (Fig. 4 and video S5, S6, S7). The size of lesions
corresponded to the description of earliest events of membrane
disruptions in dysferlinopathies [12]. We detected membrane
healing in normal (Fig. 4A–C, video S5) and also in dysferlin-
peptide treated LGMD2B (Fig. 4G–I, video S7) myotubes.
Untreated dysferlin-mutant myotubes did not exhibit repair
(Fig. 4D–F, video S6).
TAT-labeled Mutant dysferlin-peptides Localize to the ER
To investigate the mechanism elicited by the dysferlin derived
peptides, we monitored their fate after administration to
myotubes. Peptide B2, which corresponds to the DYSF p.L1341P
mutation, was fluorescently labeled with ATTO 495-ME
(YGRKKRRQRRR-C(ATTO-495-ME)-LAWGPRNMKS-
Table 1. Dysferlin-derived peptides.
Nomenclature Description Sequence of TAT-labeled dysferlin-peptides
DYSF p.293–305: LRTDALLGEFRMDVG
A1 10mer, analogous to wildtype YGRKKRRQRRR- DALLGEFRMD- amid
A2 10mer, analogous to mutant YGRKKRRQRRR- DALLREFRMD- amid
A3 15mer, analogous to wildtype YGRKKRRQRRR- LRTDALLGEFRMDVG- amid
A4 15mer, analogous to mutant YGRKKRRQRRR- LRTDALLREFRMDVG- amid
DYSF p.1434–1448: IEILAWGLRNMKSYQ
B1 10mer, analogous to wildtype YGRKKRRQRRR- LAWGLRNMKS- amid
B2 10mer, analogous to mutant YGRKKRRQRRR- LAWGPRNMKS- amid
B3 15mer, analogous to wildtype YGRKKRRQRRR- IEILAWGLRNMKSYQ- amid
B4 15mer, analogous to mutant YGRKKRRQRRR- IEILAWGPRNMKSYQ- amid
Fluorescent B2 peptide 10mer, analogous to mutant YGRKKRRQRRR- C(ATTO-495-ME)-LAWGPRNMKS- amid
Control
Nonsense peptide No analogy to DYSF sequence YGRKKRRQRRR- SMLAPWRGNK- amid
doi:10.1371/journal.pone.0049603.t001
Figure 2. Dysferlin-peptides redirect mutant dysferlin to the sarcolemma in primary human myotubes. Primary human myotubes
carrying dysferlin missense mutations were treated with the TAT-labeled dysferlin-peptides. Dysferlin was detected by anti-dysferlin ab. Nuclei are
stained with Hoechst. Missense mutated dysferlin aggregates within the myotubes (A, D). After treating human myotubes with 10mer peptides (B, E)
harboring the missense mutation mutant dysferlin can be localized at sarcolemmal sites whereas nonsense peptides (C) do not elicit this effect. (A–C)
Primary human myotubes expressing DYSF p.G299R. Experiment performed 9x. (A) No peptides added. (B) Peptide A2 (10-mer) added corresponding
to DYSF p.G299R. (C) Nonsense peptide added (control). (D–E) Primary human myotubes harboring the dysferlin mutation p.L1341P. Experiment
performed 7x. (D) No peptides added. (E) Peptide B2 (10-mer) added corresponding to DYSF p.L1341P. (F) Sarcolemmal dysferlin localization in a
normal human myotube. Bar: 10 mm. Arrows indicate reallocated dysferlin to sarcolemmal sites.
doi:10.1371/journal.pone.0049603.g002
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amid) and continuously tracked within the myotube for 14 hours
in a life cell imaging setup. The fluorescent TAT-labeled dysferlin-
peptide co-localized with calnexin, a marker of the ER. However,
this construct never appeared at the cell membrane (Fig. 5 and
video S8). Thus, mutant dysferlin-peptides do not migrate to the
sarcolemma, but instead localize to the ER. We explored the
possibility that the mutant dysferlin peptide might directly bind
dysferlin. We performed protein-binding studies between the
recombinant C2E domain of dysferlin that contained the DYSF
p.L1341P mutation and the corresponding wildtype or mutant
dysferlin peptides by surface plasmon resonance analysis. Binding
between peptides and recombinant dysferlin was not observed
(Fig. S4).
ER Stress is Reduced by Treating DYSF p.G299R
Expressing myotubes with TAT-Labeled Mutant dysferlin-
peptides
Protein misfolding may lead to the activation of the unfolded
protein response (UPR) and ER stress. Indeed, we found a
significant up-regulation of HSP5A mRNA encoding for the ER
stress sensor BiP in myotubes harboring the DYSF p.G299R
mutation compared to normal controls (Fig. 6A). The immuno-
globulin heavy chain binding protein BiP (78 kDa glucose-
regulated protein, GRP78, HSPA5) is one of the key representa-
tives of the heat shock protein family hsp 70 and was the first
namely identified member of the group of ER chaperones [13].
BiP mainly retains misfolded proteins in the ER [14] and is jointly
responsible for transferring misfolded proteins through the ER
membranes back to the cytosol. Indeed, a complex of EDEM,
ERdj5 and BiP prepares and provides terminally misfolded
proteins for proteasomal degradation [15]. In case of accumula-
tion of misfolded proteins in the ER, the HSPA5 gene transcription
coding for the protein BiP is up-regulated [16] assigning BiP the
role of an ER stress sensor [17,18,19,20]. After treatment with the
dysferlin-derived mutant peptides we could detect a down-
regulation of BiP mRNA expression as well as a reduction on
protein level (Fig. 6B–C, Fig. S5C). Moreover, the relative gene
expression of ATF6 is down-regulated after treatment. AFT6 is a
key transcription factor which transmits ER stress signals to the
nucleus inducing expression of ER stress-response genes [21,22].
In addition, we observed a down-regulation of gene expression of
the translation attenuator PERK (EIF2AK3) [23,24] as well as
CHOP (DDIT3), which induces ER stress mediated apoptosis
[25,26,27] (Fig. S5). Thus, specific peptide treatment decreases ER
stress in human myotubes expressing DYSF missense mutants.
Discussion
For the first time, a peptide-mediated therapy approach has
been taken in the field of muscular dystrophies redirecting a
mutant protein to the plasma membrane thereby restoring
function. We and others have demonstrated that missense mutated
dysferlin causes toxic ‘‘gain-of-function’’ through development of
amyloid fibrils and activation of ERAD, as well as loss of function
due to failure of dysferlin to anchor into its regular site of action.
We show that by adding dysferlin-peptides to the cell-penetrating
TAT peptide, constructs can enter the ER, reduce UPR stress and
Figure 3. Impaired membrane repair in dysferlin deficient myotubes was rescued by specific peptides: Laser wounding. Fluorescent
dye influx (FM1-43) in human myotubes harboring DYSF p.G299R or in normal human myotubes is shown at the time of laser wounding (0 seconds)
and 40, 60 and 120 seconds thereafter. Myotubes were wounded by irradiating a 2.562.5 mm boundary area of the plasma membrane. (A) DYSF
p.G299R, no peptide. (B) DYSF p.G299R, nonsense peptide added. (C) DYSF p.G299R, corresponding mutant peptide A2 added. (D) Normal human
myotubes, no peptides. Without peptides or after incubation with nonsense peptide FM1-43 dye rapidly spreads within the DYSF p.G299R human
myotubes. After treatment with specific peptide A2 distribution of FM1-43 is similar to normal myotubes. Arrows indicate the wounded area of the
plasma membrane. Scale bar: 10 mm. (E) Quantification of fluorescence intensity (FM1-43) before (0 seconds) and after laser wounding. Data
represent mean 6 SEM, n= 6/group. See also video S1, S2, S3, S4.
doi:10.1371/journal.pone.0049603.g003
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release missense mutant dysferlin to the sarcolemma. Moreover,
this mutant dysferlin is capable of regaining function. Dysferlino-
pathy is the only muscular dystrophy so far where a contribution of
protein misfolding to disease pathology has been described.
However, in other muscle disorders like myofibrillar myopathies,
inclusion body myopathies, nemalin myopathies, and FHL-1
mutation-associated muscle disorders protein misfolding has been
implied. All these diseases could be candidates that might benefit
from rectifying faulty protein aggregation [28,29,30,31].
Due to their low membrane permeability, peptides were long
considered to be of minimal therapeutic value. However, the
discovery of cell-penetrating peptides (CPPs) that readily cross lipid
bilayers has changed this state-of-affairs [32]. These peptides are
rich in cationic amino acids and are only about 10 to 16 amino
acids long. Today, many different CPPs have been described;
TAT, an HIV-peptide, has been the most extensively studied. We
demonstrate that uptake into mature myotubes is rapid and
efficient (Fig. 5). In vivo, the use of CPP-coupled peptides is more
complicated because CPPs lack cell-specificity. Strategies to
overcome this problem have been addressed and are based on
the physiological or biological features of the targeted organ. To
test possibilities specifically targeting skeletal muscle in vivo by
CPP-coupled peptides will be both interesting and formidable.
The fact that TAT-peptide cargo associates and co-localizes with
markers of caveolar uptake, may point towards a way to use
muscle-specific caveolae as targets [33,34].
The laser-wounding assay has been used earlier to document
the functional role of dysferlin at the cell membrane [2,35]. We
also developed an independent wounding assay that allowed us to
follow the fate of wounds on a single-cell level [36]. We used
atomic force microscopy (AFM) to damage the sarcolemma
mechanically and to observe repair kinetics. In atomic force
microscopy, a cantilever is used to scan living or solid surfaces on
nanoscale; however, interventions at the cell surface are also
Figure 4. Specific peptides cause functional recovery in dysferlin-deficient myotubes: Interventional atomic force microscopy.
Mechanical sarcolemmal wounding was induced by atomic force microscopy. In all experiments 2 mm longitudinal lesions were set. Arrows indicate
the lesion site. The instrument shown is the cantilever used for membrane wounding. (A–C) Normal human myotube 5, 19 and 30 seconds after
wounding. The lesion is hardly detectable and closes rapidly. (D–F) DYSF p.L1341P primary human myotube 6, 20 and 90 sec after wounding. The
lesion continuously increases in size. (G–I) DYSF p.L1341P primary human myotube treated with corresponding B2 peptide 6, 22 and 30 seconds after
wounding. The lesion disappears rapidly. Scale bar: 10 mm. See also video S5, S6, S7.
doi:10.1371/journal.pone.0049603.g004
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possible as shown here [37,38]. Both assays demonstrate
convincing repair of sarcolemmal wounds after treating human
myotubes harboring a dysferlin missense mutation with TAT-
labeled dysferlin-peptides. In the future, interventional atomic
force microscopy may become a valuable tool to dissect
sarcolemmal wounding and repair events on molecular level-
possibly identifying new mechanisms or proteins in a growing
family of molecules associated with membrane repair.
We are confident that dysferlin relocated to the membrane after
treatment with TAT-labeled peptides because of restored function.
However, sarcolemmal insertion of endogenous mutant dysferlin
would only unambiguously be depicted by detecting the extracel-
lular C-terminus on non-permeabilized myotubes. Because the
extracellular portion of dysferlin is only 12 amino acids in length
the generation of an antibody against this epitope has not been
successful.
Many different strategies are currently being considered to deal
with protein misfolding in various disorders. Physiological and
pharmacological chaperones and small molecules derived from
large library screens could be effective. In this context those
compounds become of increasing interest which act with higher
specificities and therefore with reduced toxicity [39]. In missense-
mutated dysferlin we have applied a membrane repair assay,
which is labor and time intensive, thus unsuitable for high
throughput screen. However, in searching for strategies to
intervene with misfolded dysferlin, we identified similarities to
approaches used to unfold mutated cystic fibrosis transmembrane
regulators (CFTR), the membrane protein affected in cystic
fibrosis. In a mechanism called transcomplementation, fragments
of the wild-type CFTR protein can rescue the functionally intact
chloride channel at the cell membrane. The restoration process
was validated in vitro and in cystic fibrosis mice in vivo [40,41]. The
mechanism of peptide-mediated relocalization is still unknown.In-
stead of delivering cDNA vector constructs encoding for truncated
proteins to the targeting tissue, here we directly administered the
short peptide itself avoiding the need of any viral gene delivery
approach. Our results confirm the cellular localization of the
peptides in the ER, but in our hands best results were achieved
with therapeutic peptides harboring the mutation and not
reflecting the wildtype sequence.
Recently, it was shown, that the isolated C2B to C2G domain as
well as the transmembrane region of dysferlin are capable of
binding to their homologous partners. These interactions form the
total dysferlin protein to a homodimer in vivo [42]. We investigated
two missense mutations located in different C2 domains of the
dysferlin protein structure: the C2B and C2E domain (Fig. S1).
Here, we show strong evidence, that the specific peptides reflecting
the dysferlin sequence itself allow some dysferlin harboring the
amino acid exchange to escape protein accumulation and
degradation to fulfill their task at the plasma membrane. This
might lead to the hypothesis, that the specific peptides may
transiently be capable of stabilizing the missense mutated proteins
during folding in the ER. Supportively, the primary up-regulation
of the ER stress sensor BiP in human myotubes expressing
misfolded dysferlin can be reversed by treatment with dysferlin
mutant peptides (Fig. 6). This would be consistent with the
reduction of the amount of misfolded proteins within the ER by
dysferlin-peptide treatment. Consequentially, gene expression of
the ER stress mediator proteins ATF6 and PERK were likewise
down-regulated after treatment as well as the expression of
CHOP, an inducer of ER stress-mediated apoptosis (Fig. S5). The
amelioration of ER stress-induced dysfunction may additively
contribute to the restoration of the cellular function. Apparently,
the amount of dysferlin at the sarcolemma required for normal
Figure 5. TAT-labeled dysferlin-peptides in primary human
myotubes localize to the ER. Peptide B2 corresponding to DYSF
p.L1341P was labeled with ATTO-495-ME fluorescent dye (red) and
added to DYSF p.L1341P human myotubes. (A) DYSF p.L1341P human
myotube immediately after addition of ATTO-495-ME-peptide B2 to
DYSF p.L1341P human myotubes, (B) after 8 minutes and (C) after 4
hours. (D) Immunostain using anti-calnexin ab (blue). Perfect co-
localization of ATTO-495-ME-peptide B2 and ER marker calnexin. No
dysferlin-peptide detected at the sarcolemma. Bar: 10 mm. See also
video S8.
doi:10.1371/journal.pone.0049603.g005
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sarcolemmal wound repair is only around 10% [43], suggesting
that a therapeutic approach might even be effective despite an
incomplete rescue.
Missense mutated dysferlin has been lately shown to may escape
protein degradation by unspecific blocking of the ubiquitin-
proteasome system [44]. Bortezomib has been approved for the
therapeutically treatment of multiple myeloma and mantle cell
lymphoma taking advantage of its primary effect on cells with high
proliferation rate and therefore high protein turnover inducing cell
cycle arrest and apoptosis [45]. The application regime is limited
to the development of adverse events due to the unspecific
affection of other organ systems and the overall activation of the
unfolded protein response [46,47,48,49,50]. Taking this into
account, the long-term treatment of chronic diseases ideally relies
on the specific targeting of the particular misfolded candidate
protein and the stabilization of cellular homeostasis by reducing
ER-stress related dysfunction. The dysferlin-derived peptide
treatment provides a promising approach to fulfill these criteria.
Imaging studies after administration of labeled peptides in an
animal model would provide further insights regarding the
systemic tissue distribution and functional specificity.
We conclude, that the TAT-labeled dysferlin-specific peptides
promote mutant dysferlin to reallocate within the cell and to
regain function. The peptides function in the ER by interfering
with the accumulation of misfolded dysferlin and thereby reducing
ER stress in patients’ myotubes.
Materials and Methods
Ethics Statement: Patients and Patient Material
Muscle biopsy specimens from patients with LGMD2B
(dysferlin mutations) were obtained for diagnostic purposes and
from normal controls were obtained during hip surgery (Ethical
approval EA1/203/08). All studies were performed according to
the declaration of Helsinki and were approved by the local ethical
committee (Ethics Committee – Charite´, University Medicine
Berlin). Written informed consent was obtained from all subjects.
The patients with dysferlinopathy were affected by the following
dysferlin mutations: homozygous c.4022T.C (patient 1), com-
pound heterozygous c.855+1delG/c.895G.A (patient 2).
Figure 6. TAT-labeled dysferlin-peptides reduce the expression of the ER stress sensor BiP. (A) In DYSF p.G299R human myotubes HSPA5
gene expression is significantly up-regulated. Data represent median + SEM, n= 9/group. (B and C) Mutant peptides decrease HSPA5 gene
expression in DYSF p.G299R human myotubes most effectively (RT-PCR). Consequently, treatment with specific peptide A2 reduces BiP protein
expression. C1: no peptides added; C2: addition of nonsense peptide; C3: treatment with specific peptide A2. The nonsense peptide serves as a
control and its amino-acid sequence has no analogy to dysferlin. Data represent median + SEM, n = 3/group. Fig. S5 provides additional information
on statistics.
doi:10.1371/journal.pone.0049603.g006
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Cells and Cell Culture
C2C12 cells were obtained from DSMZ (Braunschweig,
Germany). Dysferlin-deficient C2C12 cells were a gift from Dr.
Robert Brown (University of Massachusetts School of Medicine,
Worcester, USA) [51]. Dysferlin-deficient C2C12 cell line
required puromycin (1.5 mg/ml) in the culture medium. Most
experiments on human myotubes were performed with primary
human muscle cells isolated from healthy probands and from
patients with LGMD2B: DYSF c.855+1delG and c.895G.A;
p.G299R; homozygosity for DYSF c.4022T.C; p.L1341P. Muscle
specimens were placed in 30.2 mM HEPES containing
130 mM NaCl, 3 mM KCl, 10 mM D-Glucose and subsequently
digested in 254 U/ml Collagenase CLS II (Biochrom AG, Berlin,
Germany), 100 U/ml Dispase II (Roche, Grenzach-Wyhlen,
Germany) and trypsin/EDTA at 37uC for 45 minutes. Cells were
grown in skeletal muscle cell growth medium (Promocell,
Heidelberg, Germany) supplemented with 10% fetal bovine serum
(Lonza, Cologne, Germany), 2.72 mM glutamine (GlutaMAXTM)
and gentamicin (400 mg/ml) (Gibco, Paisley, UK). Myoblasts were
purified using anti-CD56 ab-coated magnetic beads (Miltenyi
Biotech, Bergisch Gladbach, Germany). Differentiation into
myotubes was induced in DMEM containing 2% horse serum
(fusion media). The experiments shown in Fig. S3B were
performed on immortalized human muscle cells endogenously
expressing the DYSF p.L1341P mutation [52].
Dysferlin-peptides
Corresponding to wildtype dysferlin and dysferlin mutations
DYSF p.G299R and DYSF p.L1341P 10 and 15mer peptides were
synthesized and coupled to TAT (YGRKKRRQRRR) (Bio-
synthan, Berlin, Germany) (Tab.1 and Fig. S1). Peptide B2 was
fluorescently labeled with ATTO 495-ME. A nonsense peptide
without analogy to dysferlin was also generated to serve as control.
Plasmids and Transfection, Peptide Treatment
The pcDNA4/TO vector (Life Technologies GmbH/Invitro-
gen, Darmstadt, Germany) containing full-length human DYSF
cDNA-GFP-tagged was a gift from Dr. Steven Laval (Newcastle
Upon Tyne, UK). DYSF c.895G.A leading to DYSF p.G299R
and DYSF c.4022T.C leading to DYSF p.L1431P were cloned
into the vector by site-directed mutagenesis. For transfection,
C2C12 cells were maintained in fusion media for four days and
then transfected with LipofectamineTM and Plus ReagentTM
(Invitrogen, Karlsruhe, Germany). 6 and 23 hours after transfec-
tion cells were treated with TAT-labeled dysferlin-derived peptides
(10 mM). Cells were fixed 34 hours after transfection.
For the dysferlin-peptide treatment of human primary myotubes
cells were maintained in fusion media for seven days. 32, 20 and 8
hours before fixation cells were treated with TAT-labeled specific
peptides (10 mM).
Immunofluorescence and Western Blotting
HAMLET anti-dysferlin monoclonal antibody (ab) was pur-
chased from Novocastra (Newcastle Upon Tyne, UK). Monoclo-
nal mouse anti-calnexin ab was acquired from Acris (Hiddenhau-
sen, Germany). Texas red pre-labeled WGA (EY Laboratories,
San Mateo, CA, USA) was used as marker for the basal lamina.
Nuclei were stained using Hoechst 33342 (Invitrogen). Monoclo-
nal mouse anti-BiP/GRP78 antibody was obtained from BD
Biosciences (Heidelberg, Germany). Rabbit polyclonal antibody
against tubulin served as a loading control (Abcam, Cambridge
UK). Immunofluorescence and Western blotting were performed
according to standard protocols. Protein bands were quantified by
Adobe Photoshop CS4. Immunofluorescence images were col-
lected using the Leica DMI6000 (Leica Microsystems, Wetzlar,
Germany) or the Zeiss LSM 700 confocal microscope (Carl Zeiss
Microscopy GmbH, Germany) both equipped with a 636glycerin
immersion lens. Digital images were processed using the LAS AF
software (Leica) or the Zeiss LSM ZEN software 2010 (Carl Zeiss).
Images were assembled using Photoshop CS4 (64 bit).
Life Cell Imaging
For live cell imaging myoblasts were seeded in 8 well glass slide
(Lab-TekH Chamber SlideTM Coverglass Systems Nunc, Roches-
ter, New York, United States) and were incubated in fusion media
for seven days. To identify myotubes cells were stained with anti-
NCAM ab (Miltenyi Biotec, Bergisch Gladbach, Germany). For
imaging cells were placed in uncoloured DMEM (Gibco, Paisley,
UK) and incubated at 37uC and 5% CO2 (heating unit, CO2
controller and tempcontrol 37-2 from PECON, Erlbach, Ger-
many). Immediately prior to imaging ATTO-495-labeled TAT-
labeled specific peptide was added at a final concentration of
10 mM. The dysferlin-peptide distribution within myotubes was
observed for 14 hours.
Laser Wounding Assay
Laser wounding was performed on cultured myotubes as
described [35,36] with slight modifications. Briefly, before laser
wounding medium was switched to Tyrode solution
(140 mM NaCl, 5 mM KCl, 2 mM MgCl2 and 10 mM HEPES,
pH 7.2) with 2.5 mM FM 1-43 (Molecular Probes, Invitrogen,
Paisley, UK) and 2.5 mM CaCl2. Myotubes were wounded by
irradiating a 2.562.5 mm boundary area of the plasma membrane
at 50% maximum power (30-mW argon-laser) for 37 seconds using
a Zeiss-LSM 510 META confocal microscope with a 636 oil
immersion lens (Carl Zeiss Microimaging GmbH, Jena, Germany).
24 images every 20 seconds were captured after injury. Digital
images were processed using the Zeiss LSM Image Browser
software. In an area of 10610 mm directly adjacent to the injury
site the changes of fluorescent intensity were calculated with ImageJ.
Interventional Atomic Force Microscopy
Myotubes were also wounded by interventional atomic force
microscopy. These experiments were performed using the Atomic
Force Microscope (AFM) NanoWizard II (JPK Instruments, Berlin,
Germany) at 37uC with a silicon cantilever (model CSC37 from
Mikromasch, Tallinn, Estonia) with a spring constant of 0.30 N/m.
Prior to the wounding the cantilever was calibrated using the thermal
noise method. The AFM was operated in the manipulation mode. In
all experiments 2 mm longitudinal lesions were set with a force set to
40 nN. Videos were obtained with a 406 objective lens using the
ProgRes CF microscope camera (Jenoptik, Jena, Germany).
Protein-protein Interaction
The sequence encoding for the C2E domain of DYSF p.L1341P
was amplified by PCR using primers to generate XhoI and EcoRI
sites at the 59 and 39 ends. PCR products were inserted into a His-
Tag Vector pRSETA (Invitrogen, Karlsruhe, Germany). Recom-
binant proteins were over-expressed in BL 21 codon plus (DE3)
RIL cells. Proteins were solubilized with Sarcosyl N-LAUROYL-
SARCOSINE and purified using Ni-NTA columns. Dysferlin
specific peptides B1-3 spanning the mutated region of the protein
were synthesized by Biosynthan. Protein-binding studies were
performed by surface plasmon resonance analysis (Biacore 2000
with CM5 sensor chip; GE Healthcare Europe, Freiburg,
Germany).
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RNA Extraction from Cells and cDNA Synthesis from Total
RNA
Total RNA was isolated according to the NucleoSpinH RNA II
kit from Macherey-Nagel (Du¨ren, Germany). 5–10 g total RNA of
each sample was mixed with 3 ml random hexamers (50 ng/ml).
DEPC-treated water was added up to the final volume of 12 ml.
Each sample was incubated at 70uC for 10 min for primer
hybridisation and chilled on ice for at least 1 min. Samples were
briefly centrifuged and 8 ml of the reaction mix, containing 4 ml
56 first strand buffer (Gibco), 2 ml DTT (0.1 M), 1 ml dNTP mix
(10 mM), 1 ml RNAse inhibitor (RNasin 40 U), were added.
Contents of the tubes were mixed and incubated at 25uC for
5 min. 1 ml (200 U) of Superscript II RT was added before
incubating the samples at 42uC for 50 min. cDNA synthesis
reaction samples containing random hexamers were first incubat-
ed at 25uC for 10 min, followed by 50 min at 42uC. The reaction
was inactivated by incubating at 70uC for 15 min and the cDNA
was stored at 220uC.
Quantitative Real-time PCR (qRT-PCR)
To detect and quantify (as absolute number of copies or relative
amount when normalized to DNA input or additional normalizing
genes), we performed a qRT-PCR.
Total cellular RNA was reverse transcribed into DNA. By using
specific primer and FAM-TAMRA labeled probes (Table S1) in a
TaqManH PCR we analysed the expression levels of genes
compared to the housekeeping gene abl. The qPCR was
performed in an Eppendorf realplex2 Mastercycler epgradient S
instrument (Eppendorf, Hamburg, Germany). 5 ml of TaqManH
Gene Expression Master Mix (Applied Biosystems, Darmstadt,
Germany), 0.25 ml of forward and reverse primer, 0.3 ml of the
probe, and 0.2 ml H2O was added to 5 ml of the cDNA or 5 ml of
the cDNA standard. All samples were measured in triplicates.
Primer and probes for RT-PCR (TaqMan) analysis were ordered
from Tib Molbiol as complete gene expression assay or
synthesized by BioTez GmbH (Berlin, Germany) (Table S1).
Results were normalized to the housekeeping gene abl and
analyzed by the DDCt method to give fold induction as compared
with untreated control samples. Statistics were performed using
the Mann-Whitney-U-Test by Dr. Andreas Busjahn.
Supporting Information
Figure S1 Position of dysferlin-peptides used for relo-
calization experiments. 10- and 15-mer peptides from the
dysferlin sequence were synthesized and coupled to the cell
penetrating peptide TAT (YGRKKRRQRRR). Peptides A1–4
and B1–4 (Table 1) represent the amino-acid sequence corre-
sponding to DYSF p.G299R in the C2B (red) and p.L1431P in the
C2E domain (green) [53].
(TIF)
Figure S2 Nonsense peptides and peptides A4 and B1 do
not relocate mutant dysferlin to the sarcolemma. C2C12
cells were transfected with either missense-mutated dysferlin
cDNA DYSF p.G299R (upper lane) or p.L1341P (lower lane).
Transfected cells were treated with TAT-labeled dysferlin-
peptides. Bar: 10 mm.
(TIF)
Figure S3 Relocated dysferlin abuts to the basal lamina.
Primary human myotubes carrying the dysferlin missense
mutation DYSF p.G299R in (A) and immortalized human
myotubes carrying the DYSF p.L1341P mutation in (B) were
treated with the dysferlin-peptides. Dysferlin was detected by anti-
dysferlin ab (left column). Co-staining with WGA as a marker of
the basal lamina was performed (middle column). Merge is shown
at the right column. Arrows indicate the sarcolemmal reallocation
of dysferlin by the 10mer mutant dysferlin-peptides. Bar: 10 mm.
(TIF)
Figure S4 DYSF p.L1341P does not stably bind corre-
sponding dysferlin peptides. Protein binding studies were
performed by surface plasmon resonance analysis. As analyte the
recombinant C2E domain harboring DYSF p.L1341P expressed in
E.coli was used. The kinetics of interaction, the rates of association
and dissociation between the C2E and the corresponding peptides
B1, B2 and B3 were tested. There is no evidence for binding
between C2E and dysferlin peptides.
(TIF)
Figure S5 ER stress is reduced by TAT-labeled dysfer-
lin-peptides. (A) In human myotubes harboring the DYSF
p.G299R mutation specific peptides reduce the relative gene
expression of the ER stress mediators ATF6 (ATF6), EIF2AK3
(PERK) and DDIT3 (CHOP). The nonsense peptide serves as
control. Data represent median + SEM, n= 9/group. P values are
listed in (C). (B) The 15mer mutant peptide A4 also effectively
reduces ER stress, whereas both wildtype peptides A1 and A3 do
not have an equivalent effect on the relative gene expression of
ATF6, EIF2AK3 and DDIT3. Data represent median + SEM,
n=3/group. (C) Supplementary statistics to Fig. 6 and Fig. S5A.
The fold induction of each sample condition (treatment with
peptide A2 or nonsense peptide) is compared to untreated controls
DYSF p.G299R. Median 6 SEM for each condition is listed and p
values are indicated in the table; n = 9/group.
(TIF)
Table S1 Primers and probes for RT-PCR.
(DOC)
Video S1 FM1-43 uptake after laser induced damage in
DYSF p.G299R primary human myotubes. No peptides
added.
(MOV)
Video S2 FM1-43 uptake after laser induced damage in
DYSF p.G299R primary human myotubes. Nonsense
peptide added (control peptide).
(MOV)
Video S3 FM1-43 uptake after laser induced damage in
DYSF p.G299R primary human myotubes. Corresponding
peptide A2 added.
(MOV)
Video S4 FM1-43 uptake after laser induced damage in
normal primary human myotubes.
(MOV)
Video S5 Sarcolemmal injury in normal primary hu-
man myotubes induced by atomic force microscopy.
(MOV)
Video S6 Sarcolemmal injury in DYSF p.L1341P prima-
ry human myotubes induced by atomic force microsco-
py. No peptides added.
(MOV)
Video S7 Sarcolemmal injury in DYSF p.L1341P prima-
ry human myotubes induced by atomic force microsco-
py. Corresponding peptide B2 added.
(MOV)
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Video S8 Life cell imaging. ATTO-495-ME-labeled and
TAT conjugated dysferlin-peptide B2 in DYSF p.L1341P
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